Statistics on Biotechnology Use  
Business Sector
Biotechnology indicators by company size.
Unidades: Specified in each variable

;Less than 250 employees;250 and more employees;Total;
Number of companies carrying out R&D in Biotechnology;1.284;160;1.444;
% Companies by type of biotechnology used: Genetic Code;29,7;38,6;30,7;
% Companies by type of biotechnology used: Functional Units;36,6;45,5;37,6;
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;20;31,6;21,3;
% Companies by type of biotechnology used: Bioprocesses;49,5;62,6;50,9;
% Companies by type of biotechnology used: Subcellular Organisms;6,8;18,3;8,1;
% Companies by type of biotechnology used: Bioinformatics;22,1;26,6;22,6;
% Companies by type of biotechnology used: Nanobiotechnology;9,8;10,2;9,8;
% Companies by type of biotechnology used: Other;16,8;17,2;16,9;
Companies in which biotechnology activities are: Main and/or exclusive;604;25;629;
Companies in which biotechnology activities are: A secondary business line;215;47;262;
Companies in which biotechnology activities are: A necessary tool for production;465;88;553;
% Companies by final application areas of biotechnology use: Human Health;44,7;41,1;44,3;
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;16,2;12,1;15,8;
% Companies by final application areas of biotechnology use: Food Products;29,4;41,1;30,7;
% Companies by final application areas of biotechnology use: Agriculture and Forestry;25,6;20,1;24,9;
% Companies by final application areas of biotechnology use: Environment;17,3;13,9;16,9;
% Companies by final application areas of biotechnology use: Industry;12,5;13,3;12,6;
R&D personnel in Biotechnology (PP);10.452;7.291;17.743;
R&D personnel in Biotechnology (PP): Research personnel;6.309;3.136;9.445;
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;4.144;4.154;8.298;
R&D personnel in Biotechnology (PP). Women;5.369;4.538;9.907;
R&D personnel in Biotechnology (PP). Women: Research personnel;3.273;1.832;5.104;
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;2.096;2.707;4.802;
R&D personnel in Biotechnology (FTE);7.232,7;5.760,8;12.993,4;
R&D personnel in Biotechnology (FTE): Research personnel;4.671,5;2.398,3;7.069,9;
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;2.561,2;3.362,4;5.923,6;
R&D personnel in Biotechnology (FTE). Women;3.763,9;3.707,8;7.471,8;
R&D personnel in Biotechnology (FTE). Women: Research personnel;2.449,2;1.421;3.870,1;
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;1.314,8;2.286,9;3.601,6;
Expenditure on internal R&D in Biotechnology (thousands of euros);691.268;532.533;1.223.801;
1) By type of expenditure: Current expenditure;614.656;493.534;1.108.189;
1.1) Labour expenditure of research personnel;221.957;138.965;360.922;
1.2) Labour expenditure of technical and auxiliary personnel;96.161;124.379;220.540;
1.3) Other current expenditure;296.538;230.190;526.727;
2) By type of expenditure: Capital expenditure;76.612;39.000;115.612;
2.1) Land and buildings;7.247;9.596;16.843;
2.2) Equipment and tools;37.708;25.819;63.527;
2.3) Acquisition of specific R&D software;2.767;1.191;3.959;
2.4) Other R&D-specific IP products;28.890;2.394;31.284;
1.1) By origin of funds: Own funds;471.465;389.138;860.603;
1.2) By origin of funds: Funds from the Business sector;77.630;50.371;128.002;
1.3) By origin of funds: Funds from the Public Administration sector;96.976;22.523;119.498;
1.4) By origin of funds: Funds from the Higher Education sector;647;0;647;
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;1.563;11.423;12.986;
1.6) By origin of funds: Funds from the rest of the world;42.988;59.078;102.065;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);43.120;80.276;123.396;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;22.993;65.992;88.985;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;20.127;14.284;34.412;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;41,8;23,6;39,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;15,2;16,4;15,3;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;22,9;17,3;22,3;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;11,5;17;12,1;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;17,2;15,8;17,1;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;18,1;15,3;17,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;15,4;20,3;16;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;41,8;38,5;41,4;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;51;44,2;50,2;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;20,7;15,1;20,1;
% Companies with international revenues related to biotechnology activities;23;20,2;22,7;
% Companies representing international revenues related to biotechnology activities;8,2;1,3;2,1;
% International revenues related to biotechnology activities distributed in: Revenues from the EU;55,4;64,9;60,6;
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;44,6;35,1;39,4;
% International revenues related to biotechnology activities by classification: International trade in goods and services;93,9;82,8;87,8;
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;3,8;15,1;10,1;
% International revenues related to biotechnology activities by classification: Subsidies from external sources;0,7;2;1,4;
% International revenues related to biotechnology activities by classification: Other;1,7;0;0,8;
Notas:
Data referring to all companies that carry out internal R&D in Biotechnology.
 2) ' .'= numeric data equal to zero not resulting from rounding
 3) FTE: Full-Time Equivalence
Fuente: National Statistics Institute